Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Dynavax Technologies Corp. (“Dynavax” or the “Company”) (NASDAQ: DVAX). If you are interested in discussing your rights as a Dynavax shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at firstname.lastname@example.org. News reports indicate that on June 10, 2013, Dynavax announced that the U.S. Food and Drug Administration asked for additional safety data on Heplisav, Dynavax’s investigational adult hepatitis B vaccine. Reportedly, the FDA denied approval of the drug in February, deeming the safety data provided by the company insufficient to support an approval. According to analysts, this will likely require the company to conduct an additional trial on Heplisav, potentially delaying approval to 2016 and requiring over $300 million in research and development costs. In a press release, the Company also indicated it plans to continue to work on questions raised by the FDA regarding the manufacturing and testing of Heplisav. On this news, Dynavax’s share price collapsed, losing over 40% of its value. Finkelstein Thompson’s investigation focuses on what remedies shareholders may have against Dynavax or its board of directors. Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers. To learn more about Finkelstein Thompson LLP, please visit our web site at www.finkelsteinthompson.com. Attorney advertising. Prior results do not guarantee similar outcomes.